These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17407395)

  • 1. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin.
    Sorensen R
    J Manag Care Pharm; 2007 Apr; 13(3):278-83. PubMed ID: 17407395
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is intravenous immunoglobulin effective in toxic epidermal necrolysis and Stevens-Johnson syndrome?].
    Navajas L; Rada G
    Medwave; 2014 Oct; 14(9):e6024. PubMed ID: 25340656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions.
    Watad A; Amital H; Shoenfeld Y
    Lupus; 2017 Sep; 26(10):1015-1022. PubMed ID: 28420062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. You can make a difference in the administration of intravenous immunoglobulin therapy.
    Duff K
    J Infus Nurs; 2006; 29(3 Suppl):S5-14. PubMed ID: 16878850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giving intravenous immunoglobulin.
    Scherf R; White-Reid K
    RN; 2008 Jan; 71(1):29-34; quiz 35. PubMed ID: 18271361
    [No Abstract]   [Full Text] [Related]  

  • 6. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.
    Bayry J; Hartung HP; Kaveri SV
    Trends Pharmacol Sci; 2015 Jul; 36(7):419-21. PubMed ID: 26003802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One IVIG mystery solved, another demands vigilance.
    Thompson CA
    Am J Health Syst Pharm; 2012 Feb; 69(4):271-2. PubMed ID: 22302248
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol.
    Ruiz-Antorán B; Agustí Escasany A; Vallano Ferraz A; Danés Carreras I; Riba N; Mateu Escudero S; Costa J; Sánchez Santiago MB; Laredo L; Durán Quintana JA; Castillo JR; Abad-Santos F; Payares Herrera C; Sádaba Díaz de Rada B; Gómez Ontañón E
    Eur J Clin Pharmacol; 2010 Jun; 66(6):633-41. PubMed ID: 20204337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulins in dermatology. Part 1: biological mechanisms and methods of administration.
    Forbat E; Ali FR; Al-Niaimi F
    Clin Exp Dermatol; 2018 Jul; 43(5):513-517. PubMed ID: 29774583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolytic adverse events with immune globulin products: product factors and patient risks.
    Scott DE; Epstein JS
    Transfusion; 2015 Jul; 55 Suppl 2():S2-5. PubMed ID: 26174893
    [No Abstract]   [Full Text] [Related]  

  • 11. Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain.
    Darbà J; Restovic G; Kaskens L; de Agustín T
    J Clin Pharmacol; 2012 Apr; 52(4):566-75. PubMed ID: 21593279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between IGIV products: impact on clinical outcome.
    Gelfand EW
    Int Immunopharmacol; 2006 Apr; 6(4):592-9. PubMed ID: 16504921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommended indications for the administration of polyclonal immunoglobulin preparations.
    Delforge M; Farber CM; Spath P; Kaveri S; Witte T; Misbah SA; Hübner R; Haerynck F; Latinne D; Muylle L; Toungouz M; Deneys V;
    Acta Clin Belg; 2011; 66(5):346-60. PubMed ID: 22145269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin use for neurologic diseases.
    Koski CL; Patterson JV
    J Infus Nurs; 2006; 29(3 Suppl):S21-8. PubMed ID: 16878852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.
    Nosadini M; Mohammad SS; Suppiej A; Sartori S; Dale RC;
    Dev Med Child Neurol; 2016 Nov; 58(11):1180-1192. PubMed ID: 27242065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune therapy for chronic inflammatory demyelinating polyneuropathy: from clinical trials to real-life.
    Rajabally YA
    Eur J Neurol; 2010 Feb; 17(2):171-2. PubMed ID: 19845752
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunoglobulins and immune deficiency: methods of administration].
    Suarez F
    Rev Med Interne; 2005 Oct; 26 Spec No 1():25-8. PubMed ID: 16475260
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative analysis of therapeutic options used for myasthenia gravis.
    Mandawat A; Kaminski HJ; Cutter G; Katirji B; Alshekhlee A
    Ann Neurol; 2010 Dec; 68(6):797-805. PubMed ID: 21061395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is it time to re-evaluate the treatment of pemphigus?
    Leventhal JS; Sanchez MR
    J Drugs Dermatol; 2012 Oct; 11(10):1200-6. PubMed ID: 23134985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editors' Notes.
    Klein HG; Schreiber GB
    Transfusion; 2015 Jul; 55 Suppl 2():S1. PubMed ID: 26174886
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.